[go: up one dir, main page]

BR9801744A - Derivados 5-deóxi citimida - Google Patents

Derivados 5-deóxi citimida

Info

Publication number
BR9801744A
BR9801744A BR9801744A BR9801744A BR9801744A BR 9801744 A BR9801744 A BR 9801744A BR 9801744 A BR9801744 A BR 9801744A BR 9801744 A BR9801744 A BR 9801744A BR 9801744 A BR9801744 A BR 9801744A
Authority
BR
Brazil
Prior art keywords
hydrogen atom
substituted
group
citimide
cytidine derivatives
Prior art date
Application number
BR9801744A
Other languages
English (en)
Inventor
Kazuo Hattori
Tohru Ishikawa
Hideo Ishitsuka
Yasunori Kohchi
Nobuhiro Oikawa
Nobuo Shimma
Hitomi Suda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9801744A publication Critical patent/BR9801744A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS 5'-DEóXI CITIDINA".<D>. Novos derivados 5'-deóxi citidina representados pela fórmula geral (I) onde R^ 1^ é um átomo de hidrogênio ou um grupo facilmente hidrolisável sob condições fisiológicas; R^ 2^ é um átomo de hidrogênio, ou um grupo -CO-OR^ 4^ [onde R^ 4^ é um grupo hidrocarboneto reto ou ramificado, saturadY (onde Y é ciclo hexila ou fenila; n é um inteiro de 0 a 4)]; R^ 3^ é um átomo de hidrogênio, bromoestar substituído com átomo(s) de halogênio], um grupo vinila ou etinila [que pode estar substituído alquila, aralquila, ou anel aromático que pode tea que pode estar substituído para uso em terapia médica, especialmente terapia de tumor.
BR9801744A 1997-06-02 1998-06-01 Derivados 5-deóxi citimida BR9801744A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97108791 1997-06-02

Publications (1)

Publication Number Publication Date
BR9801744A true BR9801744A (pt) 2000-03-21

Family

ID=8226859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801744A BR9801744A (pt) 1997-06-02 1998-06-01 Derivados 5-deóxi citimida

Country Status (33)

Country Link
US (2) US6114520A (pt)
JP (1) JP3081185B2 (pt)
KR (1) KR100312899B1 (pt)
CN (1) CN1197871C (pt)
AR (1) AR012878A1 (pt)
AT (1) ATE440854T1 (pt)
AU (1) AU746170B2 (pt)
BR (1) BR9801744A (pt)
CA (1) CA2237368C (pt)
CO (1) CO4940436A1 (pt)
CZ (1) CZ295706B6 (pt)
DE (2) DE69841086D1 (pt)
ES (2) ES2329428T3 (pt)
FR (1) FR2763953B1 (pt)
GB (1) GB2325931B (pt)
HR (1) HRP980290A2 (pt)
HU (1) HU227852B1 (pt)
ID (1) ID19801A (pt)
IL (1) IL124661A0 (pt)
IT (1) ITMI981196A1 (pt)
MA (1) MA26503A1 (pt)
MY (1) MY128985A (pt)
NO (1) NO316609B1 (pt)
NZ (1) NZ330360A (pt)
PE (1) PE79599A1 (pt)
PL (1) PL192832B1 (pt)
RS (1) RS50010B (pt)
RU (1) RU2238278C2 (pt)
SA (1) SA98190103B1 (pt)
SG (1) SG66466A1 (pt)
TR (1) TR199800988A3 (pt)
TW (1) TW584636B (pt)
ZA (1) ZA984478B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
EP1057831B1 (en) * 1999-05-26 2004-09-22 F. Hoffmann-La Roche Ag Process for the preparation of vinyl pyrimidine derivatives
KR20030074637A (ko) 2000-12-01 2003-09-19 셀 웍스 인크. 글리코실화/갈락토실화된 펩티드, 이관능기적 링커 , 및뉴클레오티드성 단량성/중합체의 접합체, 및 관련 조성물및 사용 방법
EP1827443A1 (en) * 2004-12-03 2007-09-05 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
AU2007278000B2 (en) * 2006-07-24 2011-12-15 Matsuda, Akira 3'-ethynylcytidine derivative
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
US8637486B2 (en) * 2008-03-14 2014-01-28 Retrotope, Inc. Therapeutic substances that modulate genome methylation
US8603999B2 (en) * 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP2013508293A (ja) * 2009-10-14 2013-03-07 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
CN104926890B (zh) * 2015-06-04 2018-04-03 新乡学院 一种1,2‑o‑二乙酰基‑3,5‑o‑二苯甲酰基核糖的合成方法
MX2020008188A (es) 2018-02-02 2020-11-18 Maverix Oncology Inc Conjugados de fármacos de molécula pequeña de monofosfato de gemcitabina.
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726278B2 (pt) * 1973-03-13 1982-06-03
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
JPS5677226A (en) * 1979-11-27 1981-06-25 Taiho Yakuhin Kogyo Kk Antitumorigenic agent
JPS61500224A (ja) * 1983-10-26 1986-02-06 グリ−ル、シエルダン　ビ− 腫瘍性組織を放射線に対して増感する医薬組成物
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
CA2087540C (en) * 1991-05-27 1999-01-19 Tetsuhiko Shirasaka Composition, method and kit for potentiating antitumor activity and for curing tumor
DE4123520A1 (de) * 1991-07-16 1993-01-21 Inst Molekularbiologie Ak Mittel zur regeneration des blutbildes durch foerderung der leukozytenproliferation
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (pt) * 1992-12-18 1995-08-21 Hoffmann La Roche
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
DE69407056T2 (de) * 1993-09-14 1998-04-09 Merrell Dow Pharma 5-(1-fluorovinyl)-1h-pyrimidin-2,4-dion-derivate als antineoplastische mittel
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
TR199701435T1 (xx) * 1995-05-26 1998-03-21 F. Hoffmann-La Roche Ag İnterleukin ve pirimidin nükleositlerinin kompozisyonları

Also Published As

Publication number Publication date
HRP980290A2 (en) 1999-04-30
PE79599A1 (es) 1999-08-25
IL124661A0 (en) 1998-12-06
DE19823484A1 (de) 1998-12-03
CN1197871C (zh) 2005-04-20
MY128985A (en) 2007-03-30
FR2763953B1 (fr) 2005-01-07
TR199800988A2 (xx) 1998-12-21
GB2325931A (en) 1998-12-09
GB2325931B (en) 2001-07-25
NO982473L (no) 1998-12-03
TR199800988A3 (tr) 1998-12-21
CA2237368A1 (en) 1998-12-02
AR012878A1 (es) 2000-11-22
PL192832B1 (pl) 2006-12-29
NO982473D0 (no) 1998-05-29
RU2238278C2 (ru) 2004-10-20
ES2142763B1 (es) 2001-04-01
TW584636B (en) 2004-04-21
FR2763953A1 (fr) 1998-12-04
GB9811762D0 (en) 1998-07-29
SG66466A1 (en) 1999-07-20
CO4940436A1 (es) 2000-07-24
US6114520A (en) 2000-09-05
JPH10330395A (ja) 1998-12-15
NZ330360A (en) 1999-03-29
HUP9801256A2 (hu) 1999-05-28
ID19801A (id) 1998-08-06
HUP9801256A3 (en) 2004-03-01
ITMI981196A1 (it) 1999-11-29
US6211166B1 (en) 2001-04-03
ZA984478B (en) 1998-12-02
ES2329428T3 (es) 2009-11-25
ES2142763A1 (es) 2000-04-16
CA2237368C (en) 2009-03-03
AU6798598A (en) 1998-12-03
AU746170B2 (en) 2002-04-18
HU227852B1 (en) 2012-05-02
KR19990006547A (ko) 1999-01-25
YU22598A (sh) 2001-12-26
HU9801256D0 (en) 1998-07-28
CZ295706B6 (cs) 2005-10-12
CZ167598A3 (cs) 1998-12-16
PL326604A1 (en) 1998-12-07
RS50010B (sr) 2008-09-29
KR100312899B1 (ko) 2002-03-08
NO316609B1 (no) 2004-03-08
ATE440854T1 (de) 2009-09-15
CN1201037A (zh) 1998-12-09
SA98190103B1 (ar) 2006-04-18
MA26503A1 (fr) 2004-12-20
JP3081185B2 (ja) 2000-08-28
DE69841086D1 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
BR9801744A (pt) Derivados 5-deóxi citimida
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
FI905770A0 (fi) Uusia isoindolonijohdannaisia niiden valmistus ja käyttö
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0213877A (pt) Compostos orgânicos
IL145602A0 (en) Pharmaceutical compounds
BR0115446A (pt) Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
HRP20000791B1 (en) Platinum complex, its preparation and therapeutic application
BR9913975A (pt) Agentes farmacêuticos para o tratamento da doença de parkinson, adhd e microadenomas
BR0009696A (pt) Compostos esteróides ou seus sais, uso dos mesmos, e, formulações farmacêuticas
FI863013A0 (fi) Bakterisida framstaellningar foer anvaendning inom veterinaermedicinen.
FR2847899B1 (fr) Derives d&#39;indole-3-carboxamide, leur preparation et leur application en therapeutique
ES2114524T3 (es) Agentes con accion selectiva sobre receptores de adenosina.
BR0102377A (pt) Inibidores de não-nucleosìdeo transcriptase reversa
DK415789D0 (da) Tetracykliske antidepressive midler
ES2194457T3 (es) Complejo de platino, su preparacion y aplicacion terapeutica.
KR880011155A (ko) 이미다조피리딘유도체, 그의 제법 및 치료에의 응용
BR9812752A (pt) Derivados de 8-azabiciclo [3.2.1] octano-3-metanamina enquanto ligandos dos receptores de dopamina d2 e d3 e de serotonina 5ht1a e 5ht2
BR9900179A (pt) Processo para a preparação de um composto.
BR9907672A (pt) Derivados de 5&#39;-desoxicitidina
AR009105A1 (es) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina, su preparacion y aplicacion en terapeutica
MXPA03002914A (es) Compuestos quimicos.
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
BR9702285A (pt) Novos análogos de 20(s)-camptotecina, com anel c, solúveis em água.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements